Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can turmeric and grape compounds help slow ALS?

NCT ID NCT04654689

Disease control Sponsor: Fundación Universidad Católica de Valencia San Vicente Mártir Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested a combination of liposomed curcumin (from turmeric) and resveratrol (from grapes) plus a drug called G04CB02 in 90 people with ALS. The goal was to see if this mix could improve muscle function, thinking, and inflammation over 2 months of treatment. Participants were randomly assigned to get the active treatment or a placebo, and were followed for 4 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomed curcumin and resveratrol plus G04CB02
What this could lead to
If it works, this could point toward a way to slow ALS progression and reduce inflammation.
What could go wrong
This is a small, early-phase trial with only 90 participants. The results may not apply to all ALS patients, and the supplements may not show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

90 people

The number who actually took part.

Started

Nov 2021

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All ALS patients, over 18 years of age and with a clear diagnosis and symptomatology of ALS since at least 6 months. Exclusion Criteria: * Women under 50 years of age and childbearing age. * Tracheotomy patients. * Patients with invasive or non-invasive ventilation with positive ventilatory pressure * Patients with evidence of dementia. * Patients with alcohol or drug abuse dependency. * Patients infected with B or C hepatitis, or HIV positive * Renal patients with creatinine levels twice as high as normal markers. * Liver patients with liver markers (ALT, AST) elevated 3 times above normal levels. * Patients included in other research with drugs or therapies in the experimental phase. * Patients treated with anticoagulants or with haemostatic problems

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis

Contacts and locations

Locations

  • José Enrique de la Rubia Ortí

    Valencia, Valencia, 46007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.